First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 7, 2014, Pages 774-780

  Ozaras, Resat ^a   Mete, Bilgul ^a   Ceylan, Bahadir ^b   Ozgunes, Nail ^c   Gunduz, Alper ^d   Karaosmanoglu, Hayat ^e   Cagatay, Atahan ^a   Gokturk, Kadir ^f   Erdem, Levent ^g   Kocak, Funda ^h   Senates, Ebubekir ⁱ   Tabak, Fehmi ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^c Radiology Department   (Turkey)

^d Sisli Etfal Research and Education Hospital   (Turkey)

^e Haseki Research and Educational Hospital   (Turkey)

^f Infectious Diseases Unit Buyukcekmece Research and Education Hospital   (Turkey)

^g ISTANBUL BILIM UNIVERSITY   (Turkey)

^h Basaksehir State Hospital   (Turkey)

ⁱ GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Chronic hepatitis B; Entecavir; Tenofovir; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; TENOFOVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; TURKEY (REPUBLIC); ADOLESCENT; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902131297     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000099     Document Type: Article

References (32)

1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 (Suppl 3): S158-S168.
2. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011; 34:1145-1158.
3. Keefe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4:936-962.
4. Liaw YF, Gane E, Leung N, Zeuzem S,Wang Y, Lai CL, et al. year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486-495.
5. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M,Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-Analyses. Gastroenterology 2010; 139:1218-1229.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long them therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B up to 5 years. Gastroenterology 2006; 131:1743-1751.
7. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013; 58:505-513.
8. Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-A(2a) in clinical practice: how to manage patients suffering from side effects. Expert Opin Drug Saf 2011; 10:429-435.
9. Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int 2013; 33 (Suppl 1):137-150.
10. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol 2010; 24:183-192.
11. Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in hepatitis Be antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58:872-880.
12. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
13. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. REVEAL HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus level. JAMA 2006; 295:65-73.
14. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk evaluation of viral load elevation and associated liver disease/cancer in HBV (the REVEAL HBV) study group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686.
15. Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int 2013; 33 (Suppl 1):111-115.
16. Wong GL, Chan HL, Mak CH, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58:1537-1547.
17. Abu-Amara M, Feld JJ. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma? Semin Liver Dis 2013; 33:157-166.
18. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117.
19. Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, et al. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. J Med Virol 2006; 78: 341-352.
20. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011; 26 (Suppl 1):138-143.
21. Dogan UB, Kara B, Gumurdul Y, Soylu A, Akin MS. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 2012; 23:247-252.
22. Guzelbulut F, Ovunc AO, Cetinkaya ZA, Senates E, Gokden Y, Salturk AG, et al. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B. Hepatogastroenterology 2012; 59:477-480.
23. Ceylan B, Yardinci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, et al. Comparison of tenofovir and entecavir in patients with chronic HBV infection. Eur Rev Med Pharmacol Sci 2013; 17:2467-2473.
24. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
25. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29:100-107.
26. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, et al. Hong Kong Liver Fibrosis Study Group. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007; 46:690-698.
27. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140:132-143.
28. Leung NW, Peng CY, Sollano J, Lesmana L, Yuen MF, Jeffers L, et al. Entecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviral-naive HBeAg(+) adults with high HBV DNA: week 96 results (E.A.R.L.Y Study) (abstract no. 998). J Hepatol 2008; 48 (Suppl): S373-S374.
29. Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir-Associated Fanconi Syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 2013; 18:945-948.
30. Hall AM. Update on tenofovir toxicity in the kidney. Pediatr Nephrol 2013; 28:1011-1023.
31. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
32. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.